APIDEL is a privately-owned Swiss company offering proprietary polymeric drug delivery solutions for sustained delivery of active pharmaceutical ingredients (APIs) and for solubilisation of poorly soluble drugs. The name of the company is a combination of API (active pharmaceutical ingredients) and DEL (delivery).

Apidel’s patent-protected novel polymers are biocompatible and can be manufactured in a cost-effective and environmentally friendly way.
The polymers were invented at University of Geneva in the laboratory of Prof. Robert Gurny. Apidel has an exclusive worldwide licence from University of Geneva with an exclusive right to sub-licence.

Apidel offers solutions to pharmaceutical companies who have APIs that would benefit from a number of highly desirable product characteristics, such as controlled release in the body from a single dose for weeks or months, tissue targeting following topical application and solubilisation of poorly soluble drugs.